Oryzon Genomics S.A. (ORY.MC)

EUR 2.74

(-0.36%)

Net Debt Summary of Oryzon Genomics S.A.

  • Oryzon Genomics S.A.'s latest annual net debt in 2023 was 1.43 Million EUR , up 136.9% from previous year.
  • Oryzon Genomics S.A.'s latest quarterly net debt in 2024 Q3 was -8.44 Million EUR , down -355.41% from previous quarter.
  • Oryzon Genomics S.A. reported annual net debt of -3.87 Million EUR in 2022, up 74.08% from previous year.
  • Oryzon Genomics S.A. reported annual net debt of -14.95 Million EUR in 2021, up 50.99% from previous year.
  • Oryzon Genomics S.A. reported quarterly net debt of -8.44 Million EUR for 2024 Q3, down -355.41% from previous quarter.
  • Oryzon Genomics S.A. reported quarterly net debt of 3.3 Million EUR for 2024 Q2, up 133.14% from previous quarter.

Annual Net Debt Chart of Oryzon Genomics S.A. (2023 - 2019)

Historical Annual Net Debt of Oryzon Genomics S.A. (2023 - 2019)

Year Net Debt Net Debt Growth
2023 1.43 Million EUR 136.9%
2022 -3.87 Million EUR 74.08%
2021 -14.95 Million EUR 50.99%
2020 -30.51 Million EUR 0.0%
2019 - EUR 0.0%

Peer Net Debt Comparison of Oryzon Genomics S.A.

Name Net Debt Net Debt Difference
Atrys Health, S.A. 212.17 Million EUR 99.326%
Biotechnologies Assets SA 6.81 Million EUR 79.011%
Pharma Mar, S.A. -16.65 Million EUR 108.588%
Laboratorios Farmaceuticos Rovi, S.A. 40.1 Million EUR 96.434%